manifestation of the metabolic syndrome.
1 About 20%-40% of NAFLD patients will progress to various degrees of nonalcoholic steatohepatitis (NASH) with a proportion of these developing significant fibrosis or cirrhosis. 2, 3 There is evidence to suggest that the NAFLD phenotype is determined by a number of factors, including genetic predisposition, 4 pro-inflammatory cytokines, 5 endotoxemia 6 and gut microbiome dysbiosis. [7] [8] [9] [10] Certain diets, especially those high in fructose and fat can contribute to NASH not only by affecting hepatic inflammation and lipid metabolism, 11 but also through changes in the gut microbiome composition. In turn, gut dysbiosis is thought to mediate its effect on NAFLD through a number of mechanisms: generation of endotoxins (also known as lipopolysaccharides [LPS] ), 12 delivery of endogenous alcohol to the liver and alterations in the permeability of the gut epithelium. 8, 13 LPS is a major component of Gram-negative bacteria that is continuously released during the death of gut derived bacteria. Some studies have shown that LPS levels are elevated in patients with NAFLD. 14, 15 In animal models, infusion of LPS resulted in elevation of blood glucose and insulin levels, changes which are commensurate with consumption of a high fat diet. 12 It is thought that changes in gut microbiome composition can lead to a higher translocation of LPS and activate inflammatory response mechanisms through toll-like receptor four-dependent pathways. Although not previously studied, this process may in turn be affected by NAFLD-related genes.
Recent studies have identified two major genes-transmembrane 6 superfamily 2 (TM6SF2) and patatin-like phospholipase domain-containing protein 3 (PNPLA3)-that may account for the pre-disposition to develop NASH. [16] [17] [18] [19] TM6SF2 is widely expressed in the liver, kidney and gut tissue. 16 TM6SF2 silencing in the liver reduces very low-density lipoprotein secretion and leads to hepatic steatosis. 16, 20 In contrast, hepatic overexpression of TM6SF2 increases serum lipids. 21, 22 However, the relationship between TM6SF2 expression in the gut and endotoxemia has not been evaluated.
In this study, we examined the relationship between endotoxin and histological severity in a cohort of biopsy-confirmed NAFLD patients.
2 | ME TH ODS
| Patients
This was a post-hoc analysis of a prospectively recruited cohort. 
| Liver histology
Percutaneous liver biopsy was performed using 16-gauge Temno needles. Histological slides were read by two experienced pathologists (AWHC, PCLC) who were blinded to the clinical data. In case of discrepant interpretations, the two pathologists would review the slides together and reach a consensus. Histological scoring was based on the NASH Clinical Research Network system. 25 The NAFLD activity score was the sum of steatosis, lobular inflammation and hepatocyte ballooning scores. NASH was defined as the presence of steatosis, lobular inflammation and hepatocyte ballooning. 26 Patients with perisinusoidal and portal/periportal fibrosis, bridging fibrosis or cirrhosis were considered to have significant fibrosis (F2-4).
| Transient elastography
To strengthen the findings of liver histology, we also performed liver stiffness measurement by transient elastography (FibroScan; Echosens, Paris, France) in the majority of patients in this cohort 1 day before liver biopsy according to the instructions and training provided by the manufacturer as previously described. 27 The measurement was considered reliable if there were 10 valid acquisitions and the interquartile range-to-median ratio was <0.30. 
| Statistical analysis

| Determinants of LBP level
Since the endotoxemia biomarker LBP was associated with NASH and fibrosis, factors associated with LBP level were further evalu- 
ated. By univariate analysis, LBP level was associated with BMI, T A B L E 2 Correlation between endotoxemia and liver biomarkers
| DISCUSSION
In this large histological study, biomarkers of endotoxemia were associated with the severity of NAFLD. The observation was further [33] [34] [35] Although data are limited, treatments targeting gut immunity may also improve NASH. 36 In our study, endotoxemia was correlated with the histological severity of NAFLD, representing a convincing link from dysbiosis and intestinal permeability to liver injury. In particular, both endotoxin and free fatty acids are known to activate toll-like receptor 4 and may act synergistically to induce inflammation. 37, 38 High fat diet can increase the proportion of LPS-producing bacteria in the gut, while administration of endotoxin has been shown to induce insulin resistance and weight gain, both being central features of NAFLD. 39, 40 Unexpectedly, endotoxemia was found to be associated with TM6SF2 gene polymorphism. The link between TM6SF2 and NAFLD was first identified in an exome-wide association study. 16 Intriguingly, the gene variant also confers a more favourable lipid profile and reduces the risk of myocardial infarction. 21 The impact of TM6SF2 on NAFLD and its severity has subsequently been validated in multiple cohorts and a meta-analysis. [41] [42] [43] [44] [45] TM6SF2 knockout leads to impaired mobilisation of neutral lipids for very-low-density lipoprotein assembly in animals. 46 At first glance, the association between TM6SF2 and endotoxemia appears questionable as this is a gene involved in lipid metabolism in the liver. One should also exercise caution when interpreting the results as a dose-response per T allele at TM6SF2 rs58542926
was not observed. The association between TM6SF2 polymorphism and LBP level also only had borderline significance by univariate analysis. In contrast, PNPLA3 polymorphism was associated with LBP by univariate analysis but became insignificant after adjustment for gender, BMI and HbA 1c . So far, there has been no report on the association between PNPLA3 and gut microbiota or endotoxemia.
The findings should be further evaluated in larger studies.
However, TM6SF2 is highly expressed in the gut, if anything more so than in the liver. 46 This led us to the hypothesis that intestinal TM6SF2 further contributes to the development of NAFLD and NASH through increasing endotoxemia. Although intestinal lipid absorption is only modestly impaired in Tm6sf2À/À mice, 46 it is possible that reduced intestinal chylomicron secretion can have an effect on epithelial barrier and bacterial product absorption.
Our study has the strength of a large sample size and comprehensive clinical characterisation. Nonetheless, there are a few limitations. First, the dietary pattern has not been recorded at the time of liver biopsy. Diet is known to affect both the gut microbiota composition and endotoxemia. [47] [48] [49] However, our cohort reflects the effects of both the diet and physiological condition of typical NAFLD patients. Second, all of our subjects were Han Chinese. The difference in gut microbiome is substantial across different geographical areas. 50 Whether the same holds true for endotoxemia is currently unknown and warrants further study. Finally, this is an association study and is insufficient to prove a causal relationship. In previous studies, carriage of the rs58542926 T allele was shown to be associated with lower TM6SF2 mRNA expression in NASH patients and loss of function of TM6SF2. 16, 45 Currently, we are constructing gutspecific TM6SF2 knockout animals to fully characterise the function of intestinal TM6SF2.
In conclusion, endotoxemia is positively associated with NASH and significant fibrosis. The association between TM6SF2 polymorphism and endotoxemia warrants further investigations. The findings may shed light on the pathogenesis of NASH and inform a novel treatment target.
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